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ABSTRACT OF THE THESIS
Exercise Engagement and Longitudinal Change in Alzheimer’s Disease Biomarkers, Regional
Brain Structure and Cognitive Functioning
by
Marta Stojanovic
Master of Arts in Psychological and Brain Sciences
Washington University in St. Louis, 2018
Professor Denise Head, Chair
Past research suggests that exercise engagement may play a protective role against cognitive and
brain decline with aging. In addition, a previous study in humans that examined the association
of exercise engagement with biomarkers of Alzheimer’s disease (AD) neuropathology reported
that individuals who engaged in more exercise evidenced lower amyloid deposition estimated
with positron emission tomography (PET) and levels of cerebrospinal fluid (CSF) Aβ42.
Although the effect of exercise engagement on Alzheimer’s disease (AD) biomarkers, regional
brain structure and cognitive functioning in older adults has been studied cross-sectionally, the
longer-term effect of exercise engagement has been less examined. The current study examined
whether individuals with higher baseline exercise engagement exhibit less longitudinal change in
AD biomarkers, regional brain structure and cognitive functioning than individuals with lower
baseline exercise engagement. Another goal was to examine whether APOE, genetic risk factor
for AD, and/or BDNF genotype, gene encoding a protein linked to exercise, moderate the effect
of exercise on longitudinal changes. Individuals who were clinically normal at baseline were
administered a questionnaire on their physical exercise engagement over the prior 10-year
period. Ninety-five individuals had serial CSF samples collected to examine A42 and tau, 181
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individuals underwent multiple assessments of amyloid PET imaging with Pittsburgh Compound
B (PIB), 238 individuals had serial MRI collected to examine regional brain structure, and 327
individuals underwent multiple neuropsychological assessments of cognitive functioning. We
observed significant change in AD biomarkers over time, with CSF tau and PET-PIB levels
increasing and CSF Aβ42 levels decreasing, consistent with the AD pattern. Regional brain
structure deteriorated over time, with both volume and thickness decreasing. Longitudinal
decline was also observed for cognitive functioning, including for semantic memory, episodic
memory, processing speed, and working memory. However, the level of baseline exercise
engagement did not affect longitudinal change in AD biomarkers, regional brain volume and
thickness, or cognitive performance, with the exception of processing speed. APOE or BDNF
genotype did not moderate the longitudinal effect of exercise on structural changes or cognitive
decline, again with the exception of processing speed. For APOE ε4-positive individuals, there
was not a significant effect of exercise engagement on processing speed declines. In contrast, for
the APOE ε4-negative group, higher exercise individuals evidenced less longitudinal decline
than those with lower exercise engagement. These results suggest that physical exercise
engagement may be limited as a moderator of changes in regional brain structure and cognitive
functioning over time.

viii

Chapter 1: Introduction
With the elderly population growing at a faster rate compared to younger populations, the
increasing number of people affected by Alzheimer’s disease (AD) could lead to a public health
crisis. Even though AD is the most common form of dementia among older adults, its causes are
still not well understood. Furthermore, there is a lack of treatments that are able to stop or slow
the disease progression pointing to a need to also focus on preventative measures. Since AD
pathology appears well in advance of clinical symptoms (Jack et al., 2010), recent targets for
research have been lifestyle factors that can potentially influence or slow down the appearance of
symptoms. Physical exercise has increasingly been associated with greater cardiovascular health
in older adults, as well as with brain and cognitive health (Hillman, Erickson, & Kramer, 2008).
In addition, several studies showed that physical exercise is associated with decreased risk of
developing clinical dementia (Podewils et al., 2005; Rockwood & Middleton, 2007). The initial
observations of beneficial associations between physical exercise and both healthy and
pathological aging led to a proliferation of studies examining the effects of exercising on
development of not only dementia, but also AD pathology. Studies conducted in the last couple
of decades have observed mixed results regarding the beneficial effects of exercising (e.g.,
Colcombe et al., 2006; Smith et al., 2014; Vemuri et al., 2012; Voss et al., 2013; for review see
e.g., Kramer et al., 2006; Etnier, Nowell, Landers, & Sibley, 2006), highlighting the importance
of further investigating the association between physical activity and pathological aging.
Several methods that estimate AD pathology have originated in the past several decades,
including neuroimaging and biochemical measures. Biomarkers that quantify the degree of
amyloid plaques and neurofibrillary tangles accumulation were established. Using lumbar
puncture to measure analytes in cerebrospinal fluid (CSF) allows estimation of levels of amyloid
1

plaques and neurofibrillary tangles. Smaller quantities of amyloid-beta aggregates in CSF signify
greater accumulation of the plaques in the brain (Sunderland et al., 2003). The opposite trend is
observed for phosphorylated tau (ptau) protein, the main element of neurofibrillary tangles, with
greater levels of ptau present in CSF indicating greater AD pathology (Sunderland et al., 2003).
In addition, positron emission tomography (PET) is used to measure directly the accumulation of
amyloid-beta (A) aggregates using different radiotracers, e.g. Pittsburgh compound-B (PIB)
and Florbetapir (AV-1451) (e.g., Klunk et al., 2004). Amyloid deposition in the brain has been
associated with higher PIB uptake. Finally, disease progression is linked to axonal and neuronal
death and degeneration that results in brain atrophy (Jack et al., 2010). Increased levels of tau
protein in CSF and smaller volume and thickness of brain regions, evidenced on magnetic
resonance imaging (MRI), are suggestive of brain atrophy. All of the aforementioned biomarkers
can be used as indicators of AD pathology.
Research on the relationship of physical activity with CSF and PET biomarkers produced
discrepant results. Examining physical activity via questionnaires, active individuals had lower
levels of amyloid deposition (Okonkwo et al., 2014). However, other studies failed to show an
association between physical activity and levels of tau, ptau, and amyloid (Landau et al., 2012;
Vemuri et al., 2012). When using accelerometry, a more objective measure of physical activity,
Law and colleagues (2018) found that moderate physical activity was beneficial for AD
pathology. Looking at only engagement in aerobic exercise, several studies observed that
individuals who exercise less exhibit greater levels of tau and ptau, as well as greater amyloid
deposition as evidenced by PET-PIB and CSF A42 (Liang et al., 2010; Head et al., 2012). In
addition, exercise engagement has also been shown to moderate the relationship between APOE
genotype and PIB levels (Head et al., 2012). Individuals with an APOE ε4 allele who had greater
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levels of exercise engagement were found to have lower PIB than carriers of the allele that
engaged less in exercise, while this difference was not observed for people without an APOE ε4
allele. Finally, there is a lack of studies examining the relationship between aerobic
(cardiorespiratory) fitness and AD biomarkers.
Compared to the number of studies that looked into the relationship between exercising and
amyloid and tau deposition in humans, animal studies have been more numerous. Despite the
increased number and greater experimental control in animal research, the results still seem to be
inconsistent. Several studies reported the beneficial effect of exercising on amyloid deposition in
transgenic AD mice, but at the same time a few were not able to find this association (e.g.,
Adlard, Perreau, Pop, & Cotman, 2005; Leem et al., 2009; Pietropaolo, 2008; Wolf et al., 2006;
Moore et al., 2016; Yuede et al., 2009; Liu, Zhao, Zhang, & Shi, 2013). The discrepant results in
animal studies might be due to the use of different genetic lines, differing definitions and timing
of exercise engagement, etc. However, both human and animal research seems to find
inconsistent results about the association between physical exercise and deposition of amyloid
and tau, as signs of AD pathology.
The association between physical activity and exercise engagement and brain volume has been
more thoroughly examined. Higher levels of self-reported physical activity, exercising, and
aerobic fitness were found to be related to greater volume of different brain regions, including
hippocampus, superior frontal, parietal, and medial temporal lobe (Bugg & Head, 2011; Erickson
et al., 2009; Boyle et al., 2015; Gordon et al., 2008). Furthermore, age-related declines in medial
temporal lobe and hippocampus, and prefrontal and superior parietal cortices were found to be
attenuated by physical activity and fitness (Bugg & Head, 2011; Okinkwo, 2014; Colcombe et
al., 2003). In addition, a beneficial effect of physical activity was observed in people with
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genetic risk for AD, such that higher physical activity was associated with greater hippocampal
volume at follow-up (Smith et al., 2014). While the results of these studies seem to be more
consistent, especially for the hippocampus and medial temporal lobe, several studies found the
effect in people with early AD, but have failed to observe the association between aerobic fitness
and brain volume in clinically normal older adults (Burns et al., 2008; Honea et al., 2009).
The influence of physical activity, exercising and aerobic fitness on cognitive functioning has
been a focus of research for a number of decades because of its potential clinical utility. Hence,
there are not only cross-sectional studies in this domain, but also research that has looked at
these relationships longitudinally. Age-related cognitive decline and risk for developing AD or
dementia were found to be moderated by physical activity, exercise engagement, and aerobic
fitness (Laurin, Verreault, Lindsay, MacPherson, & Rockwood,, 2001; Kramer et al., 2006;
Barnes, Yaffe, Satariano, & Tager, 2003; Smith et al., 2014; for review see Bherer, Erickson, &
Liu-Ambrose, 2013; Erickson et al., 2009; Hillman et al., 2008). Clinically normal older adults
that engage in more physical activity and exercise and have greater aerobic fitness show better
cognitive functioning compared to more sedentary older adults across a variety of cognitive
domains (e.g., working memory, executive functioning, processing speed, and attention) and are
less likely to develop AD or dementia. In addition, individuals with an APOE ε4 allele,
especially, benefited from engaging in greater levels of physical exercise, suggesting that there
might be a differential effect of physical activity on people with and without the genetic risk for
developing AD (Schuit, Feskens, Launer, & Kromhout, 2001; Smith et al., 2001; Pizzie et al.,
2014; but also Podewils et al., 2005; Rockwood & Middleton, 2007). Observational longitudinal
studies seem to relatively consistently indicate beneficial influence of greater physical activity
and aerobic fitness on cognitive functioning over time.
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A more powerful and controlled approach to examining the effect of physical exercise is via
aerobic exercise intervention studies. Recent evidence suggests that an aerobic exercise
intervention is associated with greater gray matter volume at follow-up, including for the
hippocampus, frontal and superior temporal lobes (e.g., Colcombe et al., 2006; Erickson et al.,
2011). Likewise, there seems to be substantial evidence suggesting that engaging in an aerobic
exercise intervention is linked to enhanced performance on various cognitive domains, including
overall cognitive functioning, memory, executive functioning (Lautenschlager et al., 2008;
Kramer et al., 2006; Bherer et al., 2013; Erickson & Kramer, 2009). However, comparable to the
physical activity and exercise literature which utilizes other measures, several cross-sectional
studies failed to observe the beneficial effect of physical activity and aerobic exercise
intervention on cognitive functioning (Vemuri et al., 2012; Voss et al., 2013; Hill, Storandt, &
Malley, 1993, for meta-analysis see Etnier et al., 1997; Etnier et al., 2006). Finally, the number
of studies looking at the effect of an aerobic exercise intervention on AD biomarkers is limited.
Another gap in the literature that is gaining interest, concerns the involvement of brain-derived
neurotrophic factor (BDNF) in the effects of physical activity and exercising. BDNF is thought
to contribute to synaptic plasticity and neurogenesis (Erickson et al., 2010). Animal experiments
indicate that BDNF levels in the brain, most robustly in hippocampus, increase after exercising
(Kramer et al., 2006). Human studies observed that exercise elevates serum BDNF concentration
(Hillman et al., 2008). Given the potential role of BDNF in the beneficial effects of exercising,
looking at the gene that encodes this protein has been another line of interest. Furthermore,
genetic differences among people might explain some of the individual variability that is seen in
the effects of physical exercise on cognitive and brain health (Erickson et al., 2013). Presence of
the Met allele in the BDNF gene, compared to the Val allele, was linked to reduced BDNF
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secretion and production (Egan et al., 2003). This finding sparked interest in examining whether
the BDNF polymorphism moderates the relationship between physical activity and cognitive and
brain health. A study by Brown and colleagues, (2014) showed that increased engagement in
physical activity was linked to larger volumes of temporal lobe, medial temporal lobe, and
hippocampus. This association was only present in participants with the Val/Val genotype and
not in Met allele carriers. In addition, the differential beneficial effect of physical activity for Val
homozygotes was detected for episodic memory performance (Canivet et al., 2015). In another
study, regular physical activity engagement boosted the working memory performance of Met
carriers compared to Val homozygotes (Erickson et al., 2013). These results suggest uncertainty
around which BDNF genotype benefits from physical activity and exercising. Furthermore,
several studies failed to detect a moderating influence of BDNF genotype on brain volume
(Richter-Schmidinger et al., 2011; Kim et al., 2015) or cognitive functions (Kim et al., 2015;
Erickson et al., 2013; Mandelman & Grigorenko, 2012).
Most of the research examining the relationship between physical activity, exercising, and
aerobic fitness and AD pathology and neurodegeneration has been done cross-sectionally. While
there is some suggestion that exercising might have beneficial short-term effects, there is still a
need to investigate whether long-term benefits are also present. In terms of cognitive
functioning, several studies looked at the effect of aerobic fitness or self-reported physical
activity, but not aerobic exercise engagement more specifically. Furthermore, these studies vary
in the number and duration of longitudinal follow-ups. The equivocal results mentioned so far
and the relative dearth of longitudinal studies highlight the need to further comprehensively
investigate the effect of exercising on AD biomarkers and brain structure in particular, as well as
cognitive functioning.

6

The primary goal of this study was to examine whether level of exercise engagement at baseline
is associated with longitudinal change in biomarkers, regional brain structure, and cognitive
functioning in older adults who are clinically normal. Another goal was to investigate whether
the relationship between exercise engagement at baseline and the longitudinal trajectories of
these outcomes differ by APOE status. The primary hypothesis was that individuals with higher
baseline exercise engagement will exhibit less change in AD biomarkers, brain structure, and
cognitive functioning than individuals with lower exercise engagement. Another prediction was
that APOE genotype will moderate the effect of exercise engagement on long-term changes in
AD biomarkers, brain structure and cognitive functioning, with APOE ε4-positive individuals
with greater baseline engagement showing less change than APOE ε4-positive individuals with
lower baseline engagement. Finally, a secondary goal was to examine whether BDNF genotype
moderates exercise effects longitudinally. The hypothesis was that participants with a Met allele
will benefit less from exercise engagement and show greater change over time.
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Chapter 2: Method
2.1 Participants
Older adults, 55 to 88 years-old, were recruited from the Washington University Alzheimer
Disease Research Center. All participants were clinically normal at baseline (CDR=0) and
screened for presence or history of neurological and health illnesses or injuries. Cerebrospinal
fluid was obtained from 95 individuals at baseline. At baseline, amyloid imaging with PIB was
obtained from 181 individuals, while an MRI scan was acquired for 238 individuals. 327
participants were administered cognitive measures at baseline. Table 1 presents demographic
characteristics of each sample. All participants in each of the samples went through APOE
genotyping, however, a subset of participants did not have their BDNF genotype determined, see
Table 1. Cross-sectional analyses of exercise and structural data (n=52), as well as exercise and
amyloid and tau data (n=56), from a number of these participants have been published previously
(Head et al., 2012; Liang et al., 2010).
Table 1 Demographic Characteristics of Participants across Samples

CSF

PET-PIB

Structural MRI

Cognitive tests

95

181

238

327

63, 8, 46-79

68, 10, 46-89

69, 9, 46-95

72, 8, 44-94

61/34

118/63

153/85

200/127

16, 3, 6-20

16, 3, 6-29

16, 3, 6-24

16, 3, 6-19

APOE e4 (-/+)

61/34

125/56

159/79

207/110

BDNF met (-/+)

61/34

107/62

147/76

203/100

N
Age (mean, SD, range)
Gender (F/M)
Education (mean, SD, range)
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2.2 Measurement of Physical Exercise Engagement
2.2.1 Validity
In order to estimate exercise engagement, history of walking, running, and jogging activity for
the past 10 years was assessed with a validated questionnaire (Bowles, 2004). The measure was
significantly correlated with cardiorespiratory fitness measured via treadmill test in a sample of
5063 individuals aged 18 to 80 years. Retrospective self-report of activity for a particular year
and the aerobic fitness for that year, across 10 1-year assessment periods, evidence stable
correlations, indicating that participants across the examined age range were capable of relatively
accurate self-report over this extended time span.

2.2.2 Procedure
The questionnaire was administered by telephone. Participants were asked to describe their
exercise engagement for the preceding 10 years. They reported the number of months per year,
the number of workouts per week, the average number of miles per workout, and average time
per mile for each year they engaged in walking, running, or jogging. As described previously,
metabolic equivalent (MET) values were estimated using the compendium of physical activities
to derive the physical engagement score for each participant (Bowles, 2004; Ainsworth et al.,
2000). The average MET hours per week over the past years was used as the index of exercise
engagement.
The distribution of exercise engagement scores was heavily skewed, resulting in the decision to
treat the variable as dichotomous. The participants were divided into low and high exercise
engagement groups based on a median split, in order to ensure equal number of participants in
each of the two groups.

9

2.3 Cerebrospinal Fluid Collection, Processing and
Measurement
Cerebrospinal fluid (20-30mL) was acquired by lumbar puncture at 8am after an overnight
fasting period, as described previously (Fagan et al., 2000). Samples were gently inverted to
avoid possible gradient effects, centrifuged at low speed, and aliquoted (0.5mL) into propylene
tubes before freezing at -84C. Levels of total tau, phosphorylated tau181 (ptau181), and A42
were analyzed after a single thaw following initial freezing by enzyme-linked immunosorbent
assay (Innotest; Fujirebio [formerly Innogenetics], Ghent, Belgium]. All of the individuals who
underwent CSF collection were from the Adult and Children Study cohort to ensure that the
samples were analyzed on the same type of assay, in order to avoid a confounding variable in the
longitudinal analyses. Cross-sectional results of exercise and structural, CSF, and amyloid data
from some of these participants have been reported previously (Liang et al., 2010; Bugg & Head,
2011).

2.4 In Vivo Amyloid Imaging with PIB
In vivo amyloid imaging with positron emission tomography (PET) with [11C]PiB was
performed as described previously (Mintun et al., 2006). Simultaneously with the initiation of a
60-minute dynamic PET scan in 3-dimensional mode, approximately 12mCi of [11C]PiB was
administered intravenously. Measured attenuation factors and a ramp filter were used to
reconstruct dynamic PET images. For each participant, three-dimensional regions of interest
were created based on their individual magnetic resonance imaging scans (T1-weighted 1 X 1 X
2.5-mm magnetization-prepared rapid acquisition gradient-echo sequences). To account for the
number of binding sites in expressing regional binding values, a binding potential for each region
of interest was calculated. Mean Cortical Binding Potential (MCBP) value was obtained by
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averaging the binding potential values from the prefrontal cortex, gyrus rectus, lateral temporal,
and precuneus regions of interest. The binding values of the aforementioned four regions of
interest were chosen based on previous research indicating that these brain areas demonstrate
high value of [11C]PiB uptake among individuals with AD (Mintun et al., 2006).

2.5 MRI Acquisition and Image Processing
Imaging was performed using a Siemens TIM Trio 3T scanner or Siemens BioGraph mMRPETMR 3Tscanner (Erlangen, Germany). Up to two T1-weighted sagittal MP-RAGE scans
(TR=2400ms, TE=3.16ms, flip angle=8º, TI=1000ms, 1×1×1mm resolution) were acquired in
each subject. Cortical reconstruction and volumetric segmentation were performed with the
Freesurferv5.3-HCP-Patch image analysis suite. Technical details of this procedure have been
described previously (Dale, Fischl, & Sereno, 1999; Dale & Sereno, 1993; Fischl & Dale, 2000;
Fischl, Liu, & Dale, 2001; Fischl et al., 2002; Fischl, Sereno, & Dale, 1999a; Fischl, Sereno,
Tootell, & Dale, 1999b; Fischl et al., 2004b). Briefly, the image processing includes motion
correction and averaging of multiple volumetric T1 weighted images, removal of non-brain
tissue using a hybrid watershed/surface deformation procedure, automated Talairach
transformation, segmentation of the subcortical white matter and deep gray matter volumetric
structures intensity normalization, tessellation of the gray matter white matter boundary,
automated topology correction, and surface deformation following intensity gradients to
optimally place the gray/white and gray/cerebrospinal fluid borders at the location where the
greatest shift in intensity defines the transition to the other tissue class. Once the cortical models
are complete, the cerebral cortex is parcellated into units based on gyral and sulcal structure
(Desikan et al., 2006; Fischl et al., 2004b). Neuroanatomical labels are applied to each voxel
based on a probabilistic atlas derived from a manually labeled training set that included older
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adults (Desikan, et al. 2006). The cortical gray matter parcellations are then used to label the
associated underlying white matter (Fischl, et al. 2004b). Regions-of-interest (ROIs) included
total gray matter, total white matter, dorsal/ventral lateral prefrontal (combined caudal middle
frontal and inferior frontal gyri), superior frontal gyrus (medial and lateral portions), medial
temporal (combined hippocampus, amygdala, parahippocampus and entorhinal cortex),
hippocampus, and primary visual cortex. All volumes of the ROIs were adjusted for intracranial
volume (Buckner et al., 2004).
Cortical thickness measures are calculated as the closest distance from the gray/white boundary
to the gray/CSF boundary at each vertex on the tessellated surface (Fischl & Dale, 2000). This
method uses both intensity and continuity information from the entire three- dimensional MR
volume in segmentation and deformation procedures to produce representations of cortical
thickness. The maps are created using spatial intensity gradients across tissue classes and are
therefore not simply reliant on absolute signal intensity. A neuroanatomical label is applied to
each vertex, and average cortical thickness estimates were obtained for dorsal/ventral lateral
prefrontal (combined caudal middle frontal and inferior frontal gyri), superior frontal gyrus
(medial and lateral portions), medial temporal lobe (combined hippocampus, amygdala,
parahippocampus and entorhinal cortex), and primary visual cortex. Procedures for the
measurement of cortical thickness have been validated against histological analysis (Rosas et al.,
2002) and manual measurements (Kuperberg et al., 2003; Salat et al., 2004).

2.6 Cognitive Assessment
Neuropsychological tests were administered in order to examine cognitive functioning in
different domains. Cognitive measures were categorized into semantic memory, episodic
memory, processing speed, and working memory domains. The semantic memory composite was
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created from Category Fluency (animals and vegetables) and Word Fluency tests. Episodic
memory included WMS Logical Memory Delayed, Selective Reminding Test, and WMS
Associate Learning/Verbal Paired Associates test. The processing speed composite was produced
from Trail Making A and WAIS Digit Symbol test. Two participants from the cognitive sample
did not have processing speed measures administered. The working memory composite was
generated from WAIS Digit Span Forward and Backward, the difference between Trail B and
Trail A scores, and WAIS Letter-Number Sequencing test. All of the cognitive composites
represent the average of the standardized scores from each of the tests comprising the composite.
Each of the tasks that was part of the composites was standardized across all participants for each
time point independently. WMS Logical Memory Delayed and WMS Associate Learning/Verbal
Paired Associates tasks had two different versions from two different WMS editions across time
and participants. The raw scores of each task were standardized based on the mean and standard
deviation from the first time the group completed the task. Since each participant had a score
from only one of the test versions, the standardized scores were combined into one Logical
Memory and one Associate Learning/Verbal Paired Associated variable.

2.6 APOE and BDNF genotyping
Previous reports outline the detailed procedures for genotyping in this sample (Cruchaga, 2012;
Cruchaga, 2013). Briefly, these DNA samples were genotyped with the Illumina 610 or the
Omniexpress chip. All of the samples and genotypes underwent quality control before the
analysis (Cruchaga et al., 2012). BDNF genotyping from the data was done for BDNF Val66Met
SNP (rs 6265). APOE genotyping for both rs429358 (ABI#C_3084793_20) and rs7412
(ABI#C_904973_10) has been done with TaqMan assays as described previously (Cruchaga et
al., 2010).
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2.8 Timing of Assessments
Table 2 shows the number of assessments for each of the outcomes. Furthermore, the average
duration of the follow-up is depicted for each of the samples. In addition, the average timing
between clinical assessment and the baseline measure of each of the outcome, as well the timing
between clinical assessment and exercise assessment, is shown. Finally, average time elapsed
between exercise and the baseline outcome measures is reported. Exercise assessment always
preceded the baseline measure of all outcomes.
Table 2 Number of Assessments and Timing (in years) between the following assessments

CSF

PET-PIB

Structural MRI

Cognitive tests

Clinical and exercise assessment
(mean, SD, range)

0.51, 0.58,
0.01-2.70

0.45, 0.5,
0.01-2.70

0.42, 0.47,
0.01-2.70

0.40, 0.43,
0.01-2.70

Clinical and baseline outcome
assessment (mean, SD, range)

1.25, 1.30,
0.06-4.47

1.70, 1.80,
0.03-7.78

1.59, 1.70,
0.03-8.95

1.17, 1.21,
0-7.96

Exercise and baseline outcome
assessment (mean, SD, range)

1.36, 1.22,
0.01-5.33

1.73, 1.81,
0.01-7.25

1.64, 1.71,
0.01-8.26

1.22, 1.00,
0.03-7.87

Follow-up period
(mean, SD, range)

2.42, 1.72,
0.01-6.47

3.04, 2.43,
0.01-8.52

3.23, 2.51,
0.01-9.35

3.98, 2.36,
0.01-10.38

Number of assessments of
outcome (mean, SD, range)

1.43, 0.53,
1-3

1.48, 0.68,
1-4

1.66, 0.81,
1-5

3.59, 2.13,
1-10

2.9 Statistical Analyses
All analyses were conducted using R statistical software (RStudio Team, 2005). R package nlme
was used for the analyses (Pinheiro et al., 2018). A series of linear mixed-effects models was
performed. A full model included time, exercise group, and APOE (or BDNF) genotype, as well
as all possible interaction terms. Time and intercept were random effects. Separate models were
constructed to include APOE vs BDNF genotype. Variables included as covariates in each of the
models were baseline age, education, gender, clinical dementia rating, and health composite.
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Since all participants had CDR of 0 at baseline, the clinical dementia rating variable coded for
change in CDR over time versus no change in CDR over time. Health composite represented
accumulated count of the current or past instances of the following conditions: stroke, diabetes,
seizures, traumatic brain injury, hypertension, Huntington’s disease, Parkinson’s disease,
cardiovascular disease, and depression. In the next step of the analysis, the highest order
interaction term, (i.e., the three-way interaction between time, exercise group, and APOE (or
BDNF) genotype) was excluded from the model. A likelihood ratio test was conducted testing
whether the two models, with and without the three-way interaction, were significantly different.
If the models were not significantly different based on the Chi-square test (p<0.05), the term was
dropped, otherwise, it was retained in the model. This likelihood ratio test was done for all three
two-way interactions as well. Nonsignificant terms were excluded in a stepwise manner until a
final model included significant higher-order terms and/or lowest-order terms. This analytical
procedure was done for the following outcome measures: CSF A42, CSF tau, CSF ptau, PETPIB, structural outcomes, and cognitive outcomes. Outliers were examined for each of the
outcome and defined as values of the dependent variable above or below three standard
deviations from the mean. If outliers were present, separate models were conducted with and
without them.
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Chapter 3: Results
3.1 General Results
Time was found to be a significant predictor of outcome trajectories in all of the models. The
linear trends were consistent with disease progression. Levels of CSF amyloid decreased over
time, while levels of MCBP, CSF tau and ptau increased. Volume and thickness of all ROIs
decreased over time. Lastly, decline in performance was observed for all cognitive outcomes.
The three-way interaction between exercise engagement, APOE (or BDNF genotype), and time
was not significant in any of the models, except for processing speed, see below for details. The
following results for each of the outcomes relate to other interactions and main effects. The
effects that differed in the models that excluded outliers are noted.

3.2 Cerebrospinal Fluid Outcomes
3.2.1 CSF A42
In the model with APOE genotype, there were no significant two-way interactions, see Table 3.
A significant effect of APOE genotype (=-221.81, SE=68.97, CI = -349.92 - -75.69) was
observed in the final model, such that people with positive APOE ε4 allele had smaller baseline
level of A42 than people with the negative allele. There was not a significant effect of exercise
engagement on baseline level for A42 (=-15.62, SE=68.46, CI = -151.72 – 120.47), see Figure
1.
Table 3 CSF A42

Effect

Time

A42 APOE

A42 BDNF

First
model

Final
model

First
model

Final
model

-3.16

-7.50

-3.40

-7.45
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Exercise group

0.60

-0.58

-0.09

-0.35

APOE/BDNF genotype

-1.26

-3.21

-0.80

-0.82

CDR change

0.92

1.1

1.01

1.11

Gender

0.67

0.51

0.94

1.05

Age

-1.11

-1.20

-1.07

-1.11

1.0

0.94

1.38

1.37

Health Composite

-1.28

-1.32

-0.88

-0.94

Time x Exercise group

-1.12

-1.35

Exercise group x
APOE/BDNF genotype

-1.29

0.01

Time x APOE/BDNF
genotype

-0.32

0.11

Time x Exercise group x
APOE/BDNF genotype

0.29

0.91

Education

Note: Data represent t-values ; bold = significant at p<.05

17

Figure 1 Individual profiles of CSF A42 over time

The two-way interactions between exercise engagement, BDNF genotype, and time were nonsignificant. The final model did not evidence a significant effect of BDNF genotype (=-32.84,
SE=72.03, CI = -176.04 – 110.36), or exercise engagement (=2.94, SE=72.28, CI = -140.76 –
146.64), see Table 3.

3.2.2 CSF Tau and Ptau
The following results apply to both tau and ptau outcomes for models with APOE genotype. A
significant interaction between time and APOE genotype was observed, indicating that
individuals with the APOE ε4 allele exhibited greater increase in tau and ptau over time
compared to people without the ε4 risk allele (see Table 4). None of the other two-way
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interactions were significant. Final models also included a significant main effect of APOE
genotype (=94.85, SE=28.15, CI = 35.78 – 153.93; =11.59, SE=4.92, CI = 1.81 – 21.37), such
that people with positive APOE ε4 allele had greater baseline level of tau and ptau than people
without the positive allele. There was not a significant main effect of exercise engagement on
baseline levels of tau or ptau (=13.79, SE=28.81, CI = -42.15 – 69.74; =4.04, SE=4.68, CI = 5.26 – 13.33), see Figure 2.
Table 4 CSF tau and ptau

Effect

tau APOE

tau BDNF

ptau APOE

ptau BDNF

First
model

Final
model

First
model

Final
model

First
model

Final
model

First
model

Final
model

Time

1.79

3.03

3.02

5.62

1.91

3.22

3.59

5.65

Exercise group

0.08

0.49

0.82

0.33

0.20

0.86

1.04

0.92

APOE/BDNF genotype

1.85

3.19

0.93

0.67

1.28

2.36

1.29

1.18

CDR change

1.64

1.55

1.50

1.31

1.31

1.20

1.22

1.01

Gender

0.89

1.03

0.68

0.63

1.16

1.37

1.15

1.12

Age

2.86

2.91

2.65

1.98

1.95

2.03

1.82

2.07

Education

-1.64

-1.60

-2.06

-1.93

-1.50

-1.48

-1.91

-1.78

Health Composite

0.94

1.04

0.69

0.72

1.10

1.26

1.09

1.11

Time x Exercise group

0.33

0.21

0.39

-0.61

Exercise group x
APOE/BDNF genotype

0.61

-0.93

0.56

-0.93

Time x APOE/BDNF
genotype

2.03

-0.18

2.57

Time x Exercise group x
APOE/BDNF genotype

-0.15

-0.35

-1.34

2.65

Note: Data represent t-values ; bold = significant at p<.05
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2.34

-0.37

-0.02

Figure 2 Individual profiles of CSF tau over time

In the final models with BDNF genotype, no significant main effects or interactions were
observed (see Table 4).

3.3 PET-PIB Outcome
In the APOE genotype model, only the two-way interaction between time and APOE genotype
was significant (=4.11x10-5.10, SE=1.02x10-5, CI = 2.09x10-5 – 6.13x10-5), see Table 5.
Individuals with the genetic risk factor evidenced greater increase in MCBP over time than
individuals without the APOE ε4 allele, see Figure 3. Besides this interaction, the final model
included a significant main effect of APOE genotype (=0.10, SE=0.03, CI = 0.04 – 0.15). In
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addition, a significant main effect of exercise group was observed (=-0.05, SE=0.02, CI = -0.10
- -5.32), indicating that people in the high exercise group had smaller baseline level of MCBP
compared to the people in low exercise group, see Figure 4. However, when outliers were
excluded the model did not include a significant main effect of exercise (p=0.30).
Figure 3 PET-PIB across APOE/BDNF genotypes and exercise groups
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Figure 4 Individual profiles of PET-PIB over time

In the final model with BDNF genotype, no significant main effects or interactions were
observed, see Table 5 and Figure 4.
Table 5 PET-PIB

Effect

PET-PIB APOE

PET-PIB BDNF

First
model

Final
model

First
model

Final
model

Time

1.55

1.88

2.52

4.54

Exercise group

-2.6

-2.19

-2.72

-1.88

APOE/BDNF genotype

1.58

3.55

-1.1

0.15

22

CDR change

2.80

2.79

3.17

3.05

Gender

-1.87

-1.65

-1.59

-1.51

Age

1.53

1.42

1.36

1.18

Education

0.51

0.44

0.28

0.30

Health Composite

0.23

0.16

0.24

0.15

Time x Exercise group

-0.52

-0.47

Exercise group x
APOE/BDNF

1.36

1.75

Time x APOE/BDNF

3.05

Time x Exercise group x
APOE/BDNF

-0.40

4.04

0.19
-0.72

Note: Data represent t-values; bold = significant at p<.05

3.4 MRI Outcomes
The following results are applicable to both regional volume and regional thickness outcomes in
the models with APOE genotype. No significant two-way interactions or main effects were
observed for any of the outcomes in the APOE models, see Tables 6-10 and Figures 5-6 for
examples.
Table 6 MRI outcomes (volume): Grey matter and White matter

Effect

Grey matter
APOE

Grey matter
BDNF

White matter
APOE

White matter
BDNF

First
model

Final
model

First
model

Final
model

First
model

Final
model

First
model

Final
model

Time

-7.87

-11.47

-6.03

-11.21

-4.69

-7.61

-5.07

-7.56

Exercise group

0.83

1.22

2.39

2.83

-0.59

-0.36

-0.25

0.33

APOE/BDNF genotype

-0.58

-0.94

3.73

3.85

0.71

0.84

1.45

1.91

CDR change

-4.07

-4.19

-4.15

-4.17

-2.17

-2.19

-2.28

-2.34

Gender

-3.22

-3.39

-3.37

-3.49

-1.55

-1.58

-1.94

-2.0
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Age

-12.3

-12.18

-12.5

-12.5

-9.91

-9.95

-10.3

-10.3

Education

-0.75

-0.76

-0.72

-0.74

-0.72

-0.73

-0.55

-0.63

Health Composite

-2.24

-2.25

-2.23

-2.24

0.20

0.19

-0.12

-0.12

Time x Exercise group

1.47

0.58

Exercise group x
APOE/BDNF

-0.52

-3.01

Time x APOE/BDNF

1.33

Time x Exercise group x
APOE/BDNF

-0.53

0.80

1.14

-0.13

-1.99

-0.36

-0.29

0.57

0.25

0.18

0.08

-3.13

-2.19

Note: Data represent t-values; bold = significant at p<.05
Table 7 MRI outcomes (volume): Dorsal/ventral lateral prefrontal and Medial temporal lobe

Effect

Dorsal/ventral
lateral PFC APOE

Dorsal/ventral
lateral PFC BDNF

Medial temporal
APOE

Medial temporal
BDNF

First
model

Final
model

First
model

Final
model

First
model

Final
model

First
model

Final
model

Time

-3.91

-5.31

-2.68

-12.57

-6.70

-12.71

-6.37

-12.57

Exercise group

-0.40

-0.17

1.59

-0.11

0.58

0.05

1.06

-0.11

APOE/BDNF
genotype

-1.65

-1.58

3.30

1.24

-0.01

-1.15

CDR change

-0.66

-0.68

-0.81

-7.32

-6.71

-6.81

-7.33

-7.32

Gender

-1.89

-1.79

-2.14

-3.0

-2.79

-2.92

-2.93

-3.0

Age

-8.04

-8.06

-8.72

-8.1

-8.41

-8.39

-8.27

-8.1

Education

-0.21

-0.20

-0.02

-0.84

-0.60

-0.59

-0.76

-0.84

Health
Composite

-1.27

-1.27

-1.35

0.78

0.32

0.29

0.67

0.78

Time x Exercise
group

0.65

-0.35

Exercise group x
APOE/BDNF

0.38

-3.21

-

24

2.20

-0.17

-0.33

-0.95

-2.01

1.24

-

Time x
APOE/BDNF

1.54

0.10

-0.82

-0.23

Time x Exercise
group x
APOE/BDNF

-0.80

0.49

0.44

0.83

Note: Data represent t-values; bold = significant at p<.05
Table 8 MRI outcomes (volume): Superior frontal gyrus and Hippocampus

Effect

Hippocampus
APOE

Hippocampus
BDNF

Superior frontal
gyrus APOE

Superior frontal
gyrus BDNF

First
model

Final
model

First
model

Final
model

First
model

Final
model

First
model

Final
model

Time

-6.93

-13.13

-6.83

-13.08

-6.93

-10.10

-4.79

-9.90

Exercise group

0.37

0.44

0.92

0.17

0.85

1.11

1.22

0.63

APOE/BDNF genotype

0.04

-0.56

2.14

1.52

-0.59

-0.34

1.59

1.06

CDR change

-6.59

-6.62

-7.38

-7.38

-2.03

-2.11

-1.89

-1.91

Gender

-2.65

-2.67

-2.8

-2.88

-2.26

-2.39

-2.37

-2.44

Age

-10.2

-10.2

-10.3

-10.1

-8.76

-8.71

-8.81

-8.75

Education

-0.46

-0.46

-0.68

-0.75

-1.48

-1.48

-1.16

-1.21

Health Composite

0.36

0.36

0.26

0.84

-1.63

-1.65

-1.82

-1.76

Time x Exercise group

-0.02

0.27

0.81

-0.33

Exercise group x
APOE/BDNF

-0.19

-1.58

-0.17

-1.26

Time x APOE/BDNF

-1.04

-0.16

1.99

-0.41

Time x Exercise group
x APOE/BDNF

0.33

0.15

-0.88

0.51

Note: Data represent t-values; bold = significant at p<.05
Table 9 MRI outcomes (thickness): Medial temporal lobe and Dorsal/ventral lateral prefrontal

Effect

Medial temporal
APOE

Medial temporal
BDNF

Dorsal/ventral
lateral PFC APOE

Dorsal/ventral
lateral PFC BDNF

First
model

First
model

First
model

First
model

Final
model

Final
model
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Final
model

Final
model

Time

-3.20

-7.37

-3.06

-6.94

-3.25

-4.81

-3.21

-4.87

Exercise group

0.01

-0.51

0.29

-0.37

-0.52

0.75

1.12

1.18

APOE/BDNF
genotype

-0.28

-1.34

1.39

1.01

-2.22

-1.44

1.58

2.28

CDR change

-4.90

-4.94

-5.09

-5.09

-3.35

-3.23

-2.87

-2.93

Gender

1.26

1.25

1.31

1.29

2.72

2.89

2.69

2.66

Age

-5.49

-5.50

-5.27

-5.23

-4.79

-4.83

-4.56

-4.51

Education

0.51

0.55

0.38

0.37

0.60

0.61

0.75

0.70

Health Composite

-1.22

-1.25

-0.91

-0.86

-0.50

-0.47

-0.43

-0.39

Time x Exercise
group

-0.49

-0.30

0.75

0.26

Exercise group x
APOE/BDNF

-0.41

-0.78

1.79

-0.54

Time x
APOE/BDNF

-1.22

-0.48

0.81

1.04

Time x Exercise
group x
APOE/BDNF

0.02

0.01

-1.10

-0.24

Note: Data represent t-values; bold = significant at p<.05
Table 10 MRI outcomes (thickness): Superior frontal gyrus

Effect

Superior frontal
gyrus APOE

Superior frontal
gyrus BDNF

First
model

Final
model

First
model

Final
model

Time

-5.48

-8.41

-5.20

-8.58

Exercise group

-0.67

-0.31

-0.17

0.29

APOE/BDNF genotype

-1.41

-1.56

1.12

2.10

CDR change

-3.24

-3.27

-2.86

-2.9

Gender

2.36

2.37

2.45

2.43

Age

-5.53

-5.55

-5.22

-5.25
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Education

0.92

0.92

0.81

0.77

Health Composite

-0.72

-0.72

-0.71

-0.72

Time x Exercise group

0.89

0.89

Exercise group x
APOE/BDNF

0.25

0.13

Time x APOE/BDNF

0.79

0.65

Time x Exercise group x
APOE/BDNF

-0.25

-0.30

Note: Data represent t-values; bold = significant at p<.05
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Figure 3 Individual profiles of Dorsal/ventral lateral prefrontal cortex volume over time

28

Figure 4 Individual profiles of Medial temporal lobe volume over time

In terms of volume, there was a significant interaction between BDNF genotype and exercise
group observed for total gray matter, total white matter, and the dorsal/ventral lateral prefrontal
region (see Table 6-7). Individuals with a Met allele who were in the high exercise group showed
smaller volume of these regions at baseline compared to low exercise engagement Met carriers.
There was also a significant main effect of BDNF genotype on total grey matter and
dorsal/ventral lateral prefrontal volumes, as well as a trend for total white matter volume.
Individuals with a Met allele had greater volume of these regions at baseline than individuals
without this allele. These effects were not observed for thickness, except for a main effect of
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BDNF genotype on thickness of dorsal/ventral lateral prefrontal and superior frontal gyrus.
Individuals with positive Met allele had greater thickness of these regions than individuals
without the allele. With the exclusion of outliers, the interaction between BDNF genotype and
exercise group for total white matter failed to reach significance (p=0.053).

3.5 Cognitive Outcomes
3.5.1 Semantic Memory
There were no significant two-way interactions in either the models with APOE or BDNF
genotypes (see Table 11). The final models with APOE and BDNF genotypes showed that the
high exercise group had significantly higher baseline performance on semantic memory tasks
than the low exercise group (=0.19, SE=0.08, CI = 0.02-0.35; =0.18, SE=0.09, CI = 0.0080.35, respectively), see Figure 7. With the exclusion of outliers, main effect of exercise
engagement in BDNF model failed to reach significance (p=0.056).
Table 11 Cognitive Outcomes: Semantic memory and Episodic memory

Effect

Semantic
memory APOE

Semantic
memory BDNF

Episodic memory
APOE

Episodic
memory BDNF

First
model

Final
model

First
model

Final
model

First
model

Final
model

First
model

Final
model

Time

-3.83

-5.87

-3.0

-5.81

-2.50

-2.43

-3.24

-4.62

Exercise group

1.34

2.25

1.10

2.07

0.20

1.58

0.20

1.52

APOE/BDNF genotype

-0.71

-0.3

-0.42

-0.19

-0.90

-0.18

-0.36

0.25

CDR change

-8.72

-8.85

-8.92

-8.94

-13.8

-13.9

-14.1

-14.1

3.0

3.01

2.73

2.77

4.01

4.07

4.33

4.38

Age

-1.65

-1.67

-1.18

-1.25

-0.15

-0.14

0.34

0.29

Education

5.59

5.60

5.05

5.09

5.41

5.43

5.29

5.31

Health Composite

-0.72

-0.71

-0.5

-0.52

0.21

0.23

0.80

0.80

Gender
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Time x Exercise group

0.61

0.19

1.13

1.09

Exercise group x
APOE/BDNF genotype

0.69

0.99

1.11

0.95

Time x APOE/BDNF
genotype

1.18

0.01

-0.76

Time x Exercise group x
APOE/BDNF genotype

-1.63

-1.06

-1.23

-2.23

0.48

-1.04

Note: Data represent t-values ; bold = significant at p<.05
Figure 5 Individual profiles of semantic memory performance over time

3.5.2 Episodic Memory
A significant interaction between time and APOE genotype was observed (=-9.56x10-5,
SE=4.07x10-5, CI = -1.57x10-4 - -1.01x10-5), see Table 11. APOE ε4 allele carriers showed
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steeper decline in episodic memory performance compared to individuals without the genetic
risk factor. None of the other two-way interactions were significant. There was not a significant
main effect of exercise engagement (=0.12, SE=0.08, CI = -0.03 – 0.27) or APOE genotype
(=-0.2, SE=0.10, CI = -0.21 – 0.17) on episodic memory performance, see Figure 8.
Figure 6 Individual profiles of episodic memory performance over time

In the final models with BDNF genotype, no significant main effects or interactions were
observed, see Table 11.
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3.5.3 Processing Speed
As mentioned before, significant three-way interaction between exercise group, time, and APOE
genotype (=-2.89x10-4, SE=1.05x10-4, CI = -4.97x10-4 - -8.32x10-5) was observed (see Table
12). In individuals without the ε4 risk allele, those with greater exercise engagement showed less
steep of a decline over time in the processing speed performance compared to people who
exercised less, while the trajectories between exercise groups were not significantly different in
APOE carriers, see Figure 9-10.
Table 12 Cognitive Outcomes: Processing speed and Working memory

Effect

Processing
speed APOE

Processing
speed BDNF

Working
memory APOE

Working
memory BDNF

First
model

Final
model

First
model

Final
model

First
model

Final
model

First
model

Final
model

Time

-5.20

-5.20

-4.48

-6.66

-2.65

-3.29

-2.08

-3.41

Exercise group

0.66

0.66

0.52

1.61

0.65

1.35

0.88

1.35

APOE/BDNF genotype

-1.15

-1.15

-1.05

-0.17

-0.04

0.04

0.43

0.22

CDR change

-4.76

-4.76

-4.01

-4.04

-5.08

-6.15

-6.45

-6.48

Gender

2.24

2.24

2.01

2.05

1.87

1.86

1.28

1.27

Age

1.19

1.19

2.02

1.87

-1.34

-1.35

-1.07

-1.06

Education

2.68

2.68

2.45

2.49

4.28

4.28

4.02

4.02

Health Composite

-2.09

-2.09

-2.05

-2.07

-0.39

-0.38

-0.72

-0.72

Time x Exercise group

2.64

2.64

1.15

0.87

0.54

Exercise group x
APOE/BDNF genotype

1.39

1.39

1.36

0.28

-0.22

Time x APOE/BDNF
genotype

0.74

0.74

-.001

0.79

-0.32

Time x Exercise group x
APOE/BDNF genotype

-2.75

-2.75

-0.21

-0.73

-0.01

Note: Data represent t-values ; bold = significant at p<.05
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Figure 7 Individual profiles of processing speed performance over time

Figure 8 Processing speed across APOE genotype and exercise groups
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In the final model with BDNF genotype, no significant interactions or main effects were
observed, see Table 12. However, in the BDNF model without outliers, main effect of exercise
group was significant (p=0.02).

3.5.4 Working Memory
In the models with APOE or BDNF genotypes, no significant interactions or main effects were
observed, see Table 12 and Figure 11.
Figure 9 Individual profiles of working memory performance over time
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Chapter 4: Discussion
Researchers have focused on examining lifestyle factors as potential methods for preventing or
slowing down the progression of clinical symptoms of dementia (Podewils et al., 2005;
Rockwood and Middleton, 2007). Physical exercise has found to be associated with improved
cognitive and brain health (Hillman, Erickson, & Kramer, 2009). In addition, several studies
suggest a beneficial effect of physical activity and exercising on AD pathology, as well as a
moderating effect of exercise on the relationship between APOE genotype and AD biomarkers
(e.g., Liang et al., 2010; Okonkwo et al., 2014; Head et al., 2012). While studies have looked at
the cross-sectional association between exercising and AD biomarkers, regional brain structure,
and cognitive functioning, there is more limited research comprehensively investigating the
longitudinal effect of exercising on these outcomes. Hence, the primary goal of this study was to
examine whether the level of exercise engagement at baseline would influence the rate of change
in CSF- and PET- estimates of amyloid and tau, brain volume and thickness, and cognitive
performance. Another goal was to examine whether APOE and/or BDNF status moderate the
effects of exercise on these longitudinal trajectories.
Based on our results, exercise engagement may be limited as a moderator of changes in AD
biomarkers, regional brain structure, and cognitive functioning over time. We did not find a
significant difference between low and high exercise groups in the longitudinal trajectories of the
examined outcomes, with the exception of processing speed. Furthermore, APOE and BDNF
genotype were not found to significantly influence the relationship between exercising and the
rate of change over time. These findings are in contrast with the results of longitudinal studies
that observed higher levels of aerobic fitness and physical activity to be associated with greater
hippocampal volume and cognitive performance over time (e.g., Smith et al., 2014; Barnes et al.,
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2003; Aichberger et al., 2010; Erickson et al., 2011). Mixed results seem to be more prominent
within cross-sectional designs, however, our study points to caution when thinking about
longitudinal trajectories as well. The discrepant results could be attributed to studies focusing on
aerobic fitness, exercising, versus physical activity. These differences in scope also imply
significant variation in measurement methods, from use of aerobic exercise interventions, VO2
measurements, to 2-item self-report questionnaires. Furthermore, this dissimilarity in
measurement might potentially explain some of the mixed observations, since cross-sectional
results seem to be more consistent when examining influence of aerobic fitness compared to selfreported physical activity. Considering the lack of studies looking at exercising specifically, our
findings suggest that exercise engagement might not exert a large influence on the longitudinal
trajectories of AD biomarkers, regional brain structure, and cognitive functioning.
In terms of CSF and PET-PIB outcomes, we observed an effect of exercise engagement on levels
of PET-PIB in the final model. Participants who were in the high exercise engagement group
exhibited significantly lower MCBP compared to participants in the low exercise engagement
group. However, the association between exercising and MCBP did not differ by APOE or
BDNF genotype, as previously observed (Head et al., 2012). Furthermore, we did not observe a
significant difference between the exercise groups in the baseline levels of CSF A42, tau or ptau.
These results are somewhat in line with the study by Liang and colleagues (2012) observing
significant differences in PET-PIB and CSF A42, but not in tau or ptau. The discrepancy
between amyloid and tau might be due to the fact that tauopathy increases closer to CDR
conversions, which we controlled for (Jack et al., 2010). In addition, the lack of significant
difference between exercise groups in levels of A42 is in contrast to previous work (Liang et al.,
2010). The observation by Law and colleagues (2018) that a beneficial effect of physical activity
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existed for medium intensity levels only, points to the possibility that other factors, such as
glucose metabolism, cerebral blood flow or other lifestyle factors, might moderate the
relationship between exercising and AD biomarkers. It remains unclear how robustly exercise
engagement benefits people with AD pathology.
We found several significant cross-sectional interactions between exercise engagement and
BDNF genotype in predicting brain volumes, in the opposite direction of our predictions. A study
by Brown and colleagues (2014) also observed that Met carriers with high levels of physical
activity had smaller brain volume, specifically in the hippocampus and temporal lobe. They pose
a possibility that Val homozygotes experience greater age-related decline in brain volume and
cognitive performance compared to Met carriers (Voineskos et al., 2011; Harris et al., 2006;
Ventriglia et al., 2002), which is attenuated with increased physical activity. While we did
observe that individuals with Met allele had smaller volumes of total grey and white matter and
dorsal/ventral prefrontal cortex compared to Val homozygote, we did not find differential
decrease in volume over time for Val homozygotes versus Met carriers. The discrepancies in
findings across BDNF genotypes stand to be resolved.
Looking at cognitive outcomes, we found that the high exercise group had less decline in
performance over time on the processing speed composite. Interestingly, this was present in the
individuals without the APOE e4 allele. However, considering the number of analyses conducted
in our study, the robustness of this effect warrants further investigation. Focusing on other
cognitive domains, there was a main effect of exercising on baseline semantic memory
performance, but no effect on baseline working memory or episodic memory performance. These
results are surprising considering the relative consistency in existing literature on the longitudinal
effects of exercise on cognitive functioning. However, our study focused on exercise engagement
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while others looked at physical activity, cardiorespiratory fitness, and aerobic exercise
interventions (e.g., Laurin et al., 2001; Erickson et al., 2011; Barnes et al., 2003; Pizzie et al.,
2014). These studies also vary in the duration of their follow-up, ranging from 6 months to 6
years, with most assessing the variable of interest only at baseline and follow-up. Our sample
contains multiple assessments of the outcomes over an average of four years. A meta-analysis by
Colcombe and Kramer (2003) showed that different methodological factors, including duration
and type of intervention, can moderate the effect. A meta-analysis on studies of physical activity
and exercise engagement might elucidate factors that contribute to equivocal findings on
cognitive functioning.
There are several limitations to this study that should be mentioned and considered. Firstly, CDR
conversion was used as a covariate instead of a predictor of interest, in order to maximize the
sample size. Another potential concern is that exercise engagement was assessed via a self-report
measure. Even though we used a validated questionnaire, the measure is significantly but not
perfectly correlated with cardiorespiratory fitness. Moreover, the questionnaire was administered
via telephone instead of in-person as conducted in the validation study. Since it is a self-report
measure, there is a possibility that older adults were not able to accurately report their exercise
engagement habits over a 10-year span. In addition, although the exercise questionnaire is aimed
at assessing the overall patterns of exercise engagement, there was only one measurement of
exercise engagement. This precludes us from knowing whether exercise engagement changed
over the time frame in which the outcome measurements were obtained. It is possible that
participants changed their exercise behavior in the years following baseline measurements.
Finally, the long-term beneficial effect of exercising might not be robust enough to be detected
with our sample size. In addition, there is a concern of the generalizability of the results, since
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our sample represents majority White, middle-class, educated older adults. Due to these
limitations, presence of outliers, and a high number of conducted models in the study, even
significant results might not be robust and should be interpreted with caution.
To our knowledge, this is one of few longitudinal studies to comprehensively examine the effect
of exercise engagement on AD biomarkers, regional brain structure, and cognitive functioning.
Future studies should include direct measures of cardiorespiratory fitness, such as VO2
measurements, or objective measures of physical activity, like using accelerometry. Furthermore,
intervention studies with long follow-ups can further estimate causality and effectiveness of
aerobic exercising as a prevention measure. Another future direction is to repeatedly measure
exercise engagement while following people longitudinally, thus, obtaining information about
both exercising and AD pathology and cognitive functioning over time. Additionally, extending
the range of participants’ age to middle-aged adults could provide insight into the changes in
exercise behavior over time and the most impactful age for later beneficial effects of exercising.
Moreover, having a more diverse sample in terms of race, education, socioeconomic status, and
other demographic variables, will provide better opportunity for the generalization of the results
to different populations. Additionally, examining the effect of exercise engagement in
conjunction with other life-style factors, such as nutrition, social engagement, and cognitive
exercising, can provide knowledge about individual and additive contribution of these factors to
protection against development of AD pathology and overall health. Finally, better
understanding of how the results differ based on the measurement methods and the focus on
aerobic fitness, exercise engagement versus physical activity, could provide insight into what
type of exercise regimens and physical activities influence cognitive and brain health.
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In summary, our results suggest that exercise engagement is not a robust moderator of
longitudinal trajectories of AD biomarkers, regional brain structure, and cognitive functioning.
Neither APOE nor BDNF genotypes had a significant influence on this main finding. Further
research is needed to better understand the equivocal observations of the beneficial effect of
exercising, aerobic fitness, and physical activity more broadly.

41

References
Adlard, P. A., Perreau, V. M., Pop, V., & Cotman, C. W. (2005). Voluntary exercise decreases
amyloid load in a transgenic model of Alzheimer’s disease. Journal of Neuroscience, 25(17),
4217–4221.
Aichberger, M. C., Busch, M. A., Reischies, F. M., Ströhle, A., Heinz, A., & Rapp, M. A. (2010).
Effect of physical inactivity on cognitive performance after 2.5 Years of follow-up: Longitudinal
results from the survey of health, ageing, and retirement (SHARE). GeroPsych, 23(1), 7–15.
Ainsworth, B. E., Haskell, W. L., Whitt, M. C., Irwin, M. L., Swartz, A. M., Strath, S. J., …
Emplaincourt, P. O. (2000). Compendium of physical activities: an update of activity codes and
MET intensities. Medicine and Science in Sports and Exercise, 32(9; SUPP/1), S498–S504.
Barnes, D. E., Yaffe, K., Satariano, W. A., & Tager, I. B. (2003). A Longitudinal Study of
Cardiorespiratory fitness and cognitive function in healthy older adults. Journal of the American
Geriatrics Society, 51(4), 459–465.
Bherer, L., Erickson, K. I., & Liu-Ambrose, T. (2013). A Review of the Effects of Physical Activity
and Exercise on Cognitive and Brain Functions in Older Adults. Journal of Aging Research,
2013, 1–8.
Bowles, H. R., FitzGerald, S. J., Morrow Jr, J. R., Jackson, A. W., & Blair, S. N. (2004). Construct
validity of self-reported historical physical activity. American Journal of Epidemiology, 160(3),
279-286.
Boyle, C. P., Raji, C. A., Erickson, K. I., Lopez, O. L., Becker, J. T., Gach, H. M., … Thompson, P.
M. (2015). Physical activity, body mass index, and brain atrophy in Alzheimer’s disease.
Neurobiology of Aging, 36, S194–S202.

42

Brown, B. M., Bourgeat, P., Peiffer, J. J., Burnham, S., Laws, S. M., Rainey-Smith, S. R., … Martins,
R. N. (2014). Influence of BDNF Val66Met on the relationship between physical activity and
brain volume. Neurology, 83(15), 1345–1352.
Buckner, R. L., Head, D., Parker, J., Fotenos, A. F., Marcus, D., Morris, J. C., & Snyder, A. Z.
(2004). A unified approach for morphometric and functional data analysis in young, old, and
demented adults using automated atlas-based head size normalization: reliability and validation
against manual measurement of total intracranial volume. Neuroimage, 23(2), 724-738.
Bugg, J. M., & Head, D. (2011). Exercise moderates age-related atrophy of the medial temporal lobe.
Neurobiology of Aging, 32(3), 506–514.
Burns, J. M., Cronk, B. B., Anderson, H. S., Donnelly, J. E., Thomas, G. P., Harsha, A., … Swerdlow,
R. H. (2008). Cardiorespiratory fitness and brain atrophy in early Alzheimer disease. Neurology,
71(3), 210–216.
Canivet, A., Albinet, C. T., André, N., Pylouster, J., Rodríguez-Ballesteros, M., Kitzis, A., &
Audiffren, M. (2015). Effects of BDNF polymorphism and physical activity on episodic memory
in the elderly: a cross sectional study. European Review of Aging and Physical Activity, 12(1).
Colcombe, S. J., Erickson, K. I., Raz, N., Webb, A. G., Cohen, N. J., McAuley, E., & Kramer, A. F.
(2003). Aerobic Fitness Reduces Brain Tissue Loss in Aging Humans. The Journals of
Gerontology Series A: Biological Sciences and Medical Sciences, 58(2), M176–M180.
Colcombe, S. J., Erickson, K. I., Scalf, P. E., Kim, J. S., Prakash, R., McAuley, E., … Kramer, A. F.
(2006). Aerobic Exercise Training Increases Brain Volume in Aging Humans. The Journals of
Gerontology Series A: Biological Sciences and Medical Sciences, 61(11), 1166–1170.
Colcombe, S., & Kramer, A. F. (2003). Fitness Effects on the Cognitive Function of Older Adults: A
Meta-Analytic Study. Psychological Science, 14(2), 125–130.

43

Cruchaga, C., Chakraverty, S., Mayo, K., Vallania, F. L. M., Mitra, R. D., Faber, K., … for the NIALOAD/NCRAD Family Study Consortium. (2012). Rare Variants in APP, PSEN1 and PSEN2
Increase Risk for AD in Late-Onset Alzheimer’s Disease Families. PLoS ONE, 7(2), e31039.
Cruchaga, C., Kauwe, J. S. K., Harari, O., Jin, S. C., Cai, Y., Karch, C. M., … Goate, A. M. (2013).
GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer’s Disease.
Neuron, 78(2), 256–268.
Cruchaga, C., Kauwe, J. S. K., Mayo, K., Spiegel, N., Bertelsen, S., Nowotny, P., … Goate, A. M.
(2010). SNPs Associated with Cerebrospinal Fluid Phospho-Tau Levels Influence Rate of
Decline in Alzheimer’s Disease. PLoS Genetics, 6(9), e1001101.
Dale, A.M., Fischl, B., & Sereno, M.I. (1999). Cortical surface-based analysis. I. Segmentation and
surface reconstruction. Neuroimage, 9, 179-194.
Dale, A.M., & Sereno, M.I. (1993). Improved localization of cortical activity by combining EEG and
MEG with MRI cortical surface reconstruction: a linear approach. Journal of Cognitive
Neuroscience, 5, 162-176.
Desikan, R.S., Segonne, F., Fischl, B., Quinn, B.T., Dickerson, B.C., Blacker, D., … , Killiany, R.J.
(2006). An automated labeling system for subdividing the human cerebral cortex on MRI scans
into gyral based regions of interest. Neuroimage, 31, 968-980.
Egan, M. F., Kojima, M., Callicott, J. H., Goldberg, T. E., Kolachana, B. S., Bertolino, A., …
Weinberger, D. R. (2003). The BDNF val66met Polymorphism Affects Activity-Dependent
Secretion of BDNF and Human Memory and Hippocampal Function. Cell, 112(2), 257–269.
Erickson, K I, & Kramer, A. F. (2008). Aerobic exercise effects on cognitive and neural plasticity in
older adults. British Journal of Sports Medicine, 43(1), 22–24.

44

Erickson, K. I., Prakash, R. S., Voss, M. W., Chaddock, L., Heo, S., McLaren, M., … Kramer, A. F.
(2010). Brain-Derived Neurotrophic Factor Is Associated with Age-Related Decline in
Hippocampal Volume. Journal of Neuroscience, 30(15), 5368–5375.
Erickson, K. I., Voss, M. W., Prakash, R. S., Basak, C., Szabo, A., Chaddock, L., … Kramer, A. F.
(2011). Exercise training increases size of hippocampus and improves memory. Proceedings of
the National Academy of Sciences, 108(7), 3017–3022.
Erickson, Kirk I., Banducci, S. E., Weinstein, A. M., Angus W. MacDonald, I., Ferrell, R. E., Halder,
I., … Manuck, S. B. (2013). The Brain-Derived Neurotrophic Factor Val66Met Polymorphism
Moderates an Effect of Physical Activity on Working Memory Performance. Psychological
Science, 24(9), 1770–1779.
Erickson, Kirk I., Prakash, R. S., Voss, M. W., Chaddock, L., Hu, L., Morris, K. S., … Kramer, A. F.
(2009). Aerobic fitness is associated with hippocampal volume in elderly humans. Hippocampus,
19(10), 1030–1039.
Etnier, J. L., Nowell, P. M., Landers, D. M., & Sibley, B. A. (2006). A meta-regression to examine
the relationship between aerobic fitness and cognitive performance. Brain Research Reviews,
52(1), 119–130.
Etnier, J. L., Salazar, W., Landers, D. M., Petruzzello, S. J., Han, M., & Nowell, P. (1997). The
Influence of Physical Fitness and Exercise upon Cognitive Functioning: A Meta-Analysis.
Journal of Sport and Exercise Psychology, 19(3), 249–277.
Fagan, A. M., Younkin, L. H., Morris, J. C., Fryer, J. D., Cole, T. G., Younkin, S. G., & Holtzman, D.
M. (2000). Differences in the A40/A42 ratio associated with cerebrospinal fluid lipoproteins
as a function of apolipoprotein E genotype. Annals of Neurology, 48(2), 201–210.

45

Fischl, B., & Dale, A.M. (2000). Measuring the thickness of the human cerebral cortex from magnetic
resonance images. Proceedings of National Academy of Science, 97, 11050-11055.
Fischl, B., Liu, A., & Dale, A.M. (2001). Automated manifold surgery: constructing geometrically
accurate and topologically correct models of the human cerebral cortex. IEEE Trans Med
Imaging, 20, 70-80.
Fischl, B., Salat, D.H., Busa, E., Albert, M., Dieterich, M., Haselgrove, C.,… , Dale, A.M. (2002).
Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain.
Neuron, 33, 341-355.
Fischl, B., Salat, D.H., van der Kouwe, A.J., Makris, N., Segonne, F., Quinn, B.T., & Dale, A.M.
(2004a) Sequence-independent segmentation of magnetic resonance images. Neuroimage, 23
Suppl 1, S69-84.
Fischl, B., Sereno, M.I., & Dale, A.M. (1999a). Cortical surface-based analysis. II: Inflation,
flattening, and a surface-based coordinate system. Neuroimage, 9, 195-207.
Fischl, B., Sereno, M.I., Tootell, R.B., & Dale, A.M. (1999b). High-resolution intersubject averaging
and a coordinate system for the cortical surface. Human Brain Mapping, 8, 272-284.
Fischl, B., van der Kouwe, A., Destrieux, C., Halgren, E., Segonne, F., Salat, D.H., … , Dale, A.M.
(2004b). Automatically parcellating the human cerebral cortex. Cerebral Cortex, 14, 11-22.
Head, D., Bugg, J. M., Goate, A. M., Fagan, A M., Mintun, M. A., Benzinger, T., … Morris, J. C.
(2012). Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid
Deposition. Archives of Neurology, 69(5), 636.
Kim, A., Fagan, A. M., Goate, A. M., Benzinger, T. L. S., Morris, J. C., & Head, D. (2015). Lack of
an association of BDNF Val66Met polymorphism and plasma BDNF with hippocampal volume
and memory. Cognitive, Affective, & Behavioral Neuroscience, 15(3), 625–643.

46

Gordon, B. A., Rykhlevskaia, E. I., Brumback, C. R., Lee, Y., Elavsky, S., Konopack, J. F., …
Fabiani, M. (2008). Neuroanatomical correlates of aging, cardiopulmonary fitness level, and
education. Psychophysiology, 825-838.
Harris, S. E., Fox, H., Wright, A. F., Hayward, C., Starr, J. M., Whalley, L. J., & Deary, I. J. (2006).
The brain-derived neurotrophic factor Val66Met polymorphism is associated with age-related
change in reasoning skills. Molecular psychiatry, 11(5), 505.
Hill, R. D., Storandt, M., & Malley, M. (1993). The Impact of Long-term Exercise Training on
Psychological Function in Older Adults. Journal of Gerontology, 48(1), P12–P17.
Hillman, C. H., Erickson, K. I., & Kramer, A. F. (2008). Be smart, exercise your heart: exercise
effects on brain and cognition. Nature Reviews Neuroscience, 9(1), 58–65.
Honea, R., Thomas, G. P., Harsha, A., Anderson, H. S., Donnelly, J. E., Brooks, W. M., & Burns, J.
M. (2009). Cardiorespiratory fitness and preserved medial temporal lobe volume in Alzheimer’s
Disease. Alzheimer Disease and Associated Disorders, 23(3), 188–197.
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., …
Trojanowski, J. Q. (2010). Hypothetical model of dynamic biomarkers of the Alzheimer’s
pathological cascade. The Lancet Neurology, 9(1), 119–128.
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., ... & Avsen, B. (2004).
Imaging brain amyloid in Alzheimer’s disease using the novel PET tracer, PIB. Annals of
Neuroogyl, 55, 781-789.
Kramer, A. F., Erickson, K. I., & Colcombe, S. J. (2006). Exercise, cognition, and the aging brain.
Journal of Applied Physiology, 101(4), 1237–1242.

47

Kuperberg, G.R., Broome, M.R., McGuire, P.K., David, A.S., Eddy, M., Ozawa, F., … , Fischl, B.
(2003). Regionally localized thinning of the cerebral cortex in schizophrenia. Archives of
General Psychiatry, 60, 878-888.
Laurin, D., Verreault, R., Lindsay, J., MacPherson, K., & Rockwood, K. (2001). Physical Activity
and Risk of Cognitive Impairment and Dementia in Elderly Persons. Archives of Neurology,
58(3).
Lautenschlager, N. T., Cox, K. L., Flicker, L., Foster, J. K., van Bockxmeer, F. M., Xiao, J., …
Almeida, O. P. (2008). Effect of Physical Activity on Cognitive Function in Older Adults at Risk
for Alzheimer Disease: A Randomized Trial. JAMA, 300(9), 1027.
Law, L. L., Rol, R. N., Schultz, S. A., Dougherty, R. J., Edwards, D. F., Koscik, R. L., … Okonkwo,
O. C. (2018). Moderate intensity physical activity associates with CSF biomarkers in a cohort at
risk for Alzheimer’s disease. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease
Monitoring, 10, 188–195.
Leckie, R. L., Oberlin, L. E., Voss, M. W., Prakash, R. S., Szabo-Reed, A., Chaddock-Heyman, L., …
Erickson, K. I. (2014). BDNF mediates improvements in executive function following a 1-year
exercise intervention. Frontiers in Human Neuroscience, 8.
Leem, Y.-H., Lim, H.-J., Shim, S.-B., Cho, J.-Y., Kim, B.-S., & Han, P.-L. (2009). Repression of tau
hyperphosphorylation by chronic endurance exercise in aged transgenic mouse model of
tauopathies. Journal of Neuroscience Research, 87(11), 2561–2570.
Liang, K. Y., Mintun, M. A., Fagan, A. M., Goate, A. M., Bugg, J. M., Holtzman, D. M., … Head, D.
(2010). Exercise and Alzheimer’s disease biomarkers in cognitively normal older adults:
Exercise and AD Biomarkers. Annals of Neurology, 68(3), 311–318.

48

Liu, H., Zhao, G., Zhang, H., & Shi, L. (2013). Long-term treadmill exercise inhibits the progression
of Alzheimer’s disease-like neuropathology in the hippocampus of APP/PS1 transgenic mice.
Behavioural Brain Research, 256, 261–272.
Mandelman, S. D., & Grigorenko, E. L. (2012). BDNF Val66Met and cognition: all, none, or some?
A meta-analysis of the genetic association. Genes, Brain and Behavior, 11(2), 127–136.
Landau, S. M., Marks, S. M., Mormino, E. C., Rabinovici, G. D., Oh, H., O’Neil, J. P., … Jagust, W.
J. (2012). Association of Lifetime Cognitive Engagement and Low β-Amyloid Deposition.
Archives of Neurology, 69(5), 623.
Mintun, M. A., LaRossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., … Morris, J. C.
(2006). [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer
disease. Neurology, 67(3), 446–452.
Moore, K. M., Girens, R. E., Larson, S. K., Jones, M. R., Restivo, J. L., Holtzman, D. M., … Timson,
B. F. (2016). A spectrum of exercise training reduces soluble Aβ in a dose-dependent manner in
a mouse model of Alzheimer’s disease. Neurobiology of Disease, 85, 218–224.
Okonkwo, O. C., Schultz, S. A., Oh, J. M., Larson, J., Edwards, D., Cook, D., … Sager, M. A. (2014).
Physical activity attenuates age-related biomarker alterations in preclinical AD. Neurology,
83(19), 1753–1760.
Pietropaolo, S., Sun, Y., Li, R., Brana, C., Feldon, J., & Yee, B. K. (2008). The impact of voluntary
exercise on mental health in rodents: A neuroplasticity perspective. Behavioural Brain Research,
192(1), 42–60.
Pinheiro J, Bates D, DebRoy S, Sarkar D and R Core Team (2018). nlme: Linear and Nonlinear
Mixed Effects Models. R package version 3.1-137, https://CRAN.R-project.org/package=nlme.

49

Pizzie, R., Hindman, H., Roe, C., Head, D., Grant, E., Morris, J. C., & Hassenstab, J. J. (2014).
Physical activity and cognitive trajectories in cognitively normal adults: the adult children
study. Alzheimer disease and associated disorders, 28(1), 50.
Podewils, L. J., Guallar, E., Kuller, L. H., Fried, L. P., Lopez, O. L., Carlson, M., & Lyketsos, C. G.
(2005). Physical Activity, APOE Genotype, and Dementia Risk: Findings from the
Cardiovascular Health Cognition Study. American Journal of Epidemiology, 161(7), 639–651.
Richter-Schmidinger, T., Alexopoulos, P., Horn, M., Maus, S., Reichel, M., Rhein, C., … Kornhuber,
J. (2011). Influence of brain-derived neurotrophic-factor and apolipoprotein E genetic variants
on hippocampal volume and memory performance in healthy young adults. Journal of Neural
Transmission, 118(2), 249–257.
Rockwood, K., & Middleton, L. (2007). Physical activity and the maintenance of cognitive function.
Alzheimer’s & Dementia, 3(2), S38–S44.
Rosas, H.D., Liu, A.K., Hersch, S., Glessner, M., Ferrante, R.J., Salat, D.H., … , Fischl, B. (2002).
Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology, 58,
695-701.
RStudio Team (2015). RStudio: Integrated Development for R. RStudio, Inc., Boston, MA. URL
http://www.rstudio.com/.
Salat, D.H., Buckner, R.L., Snyder, A.Z., Greve, D.N., Desikan, R.S., Busa, E., … , Fischl, B. (2004).
Thinning of the cerebral cortex in aging. Cerebral Cortex, 14, 721-730.
Schuit, A. J., M. Feskens, E. J., Launer, L. J., & Kromhout, D. (2001). Physical activity and cognitive
decline, the role of the apolipoprotein e4 allele: Medicine and Science in Sports and Exercise,
772–777.

50

Smith, J. C., Nielson, K. A., Woodard, J. L., Seidenberg, M., Durgerian, S., Hazlett, K. E., … Rao, S.
M. (2014). Physical activity reduces hippocampal atrophy in elders at genetic risk for
Alzheimer’s disease. Frontiers in Aging Neuroscience, 6.
Sunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., ... & Bartko, J.
J. (2003). Decreased β-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients
with Alzheimer disease. Jama, 289(16), 2094-2103.
Vemuri, P., Lesnick, T. G., Przybelski, S. A., Knopman, D. S., Roberts, R. O., Lowe, V. J., … Jack,
C. R. (2012). Effect of lifestyle activities on alzheimer disease biomarkers and cognition. Annals
of Neurology, 72(5), 730–738.
Ventriglia, M., Chiavetto, L. B., Benussi, L., Binetti, G., Zanetti, O., Riva, M. A., & Gennarelli, M.
(2002). Association between the BDNF 196 A/G polymorphism and sporadic Alzheimer's
disease. Molecular psychiatry, 7(2), 136.
Voineskos, A. N., Lerch, J. P., Felsky, D., Shaikh, S., Rajji, T. K., Miranda, D., ... & Kennedy, J. L.
(2011). The brain-derived neurotrophic factor Val66Met polymorphism and prediction of neural
risk for Alzheimer disease. Archives of General Psychiatry, 68(2), 198-206.
Voss, M. W., Heo, S., Prakash, R. S., Erickson, K. I., Alves, H., Chaddock, L., … Kramer, A. F.
(2013). The influence of aerobic fitness on cerebral white matter integrity and cognitive function
in older adults: Results of a one-year exercise intervention: Aerobic Fitness, White Matter, and
Aging. Human Brain Mapping, 34(11), 2972–2985.
Wolf, S. A., Kronenberg, G., Lehmann, K., Blankenship, A., Overall, R., Staufenbiel, M., &
Kempermann, G. (2006). Cognitive and Physical Activity Differently Modulate Disease
Progression in the Amyloid Precursor Protein (APP)-23 Model of Alzheimer’s Disease.
Biological Psychiatry, 60(12), 1314–1323.

51

Yuede, C. M., Zimmerman, S. D., Dong, H., Kling, M. J., Bero, A. W., Holtzman, D. M., …
Csernansky, J. G. (2009). Effects of voluntary and forced exercise on plaque deposition,
hippocampal volume, and behavior in the Tg2576 mouse model of Alzheimer’s disease.
Neurobiology of Disease, 35(3), 426–432.

52

